Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News Alert: FDA, FTC warn 10 companies for making ‘fraudulent claims’ about unapproved diabetes supplements

News You Need to Know Today
News Alert: FDA, FTC warn 10 companies for making ‘fraudulent claims’ about unapproved diabetes supplements
Thursday, September 9, 2021
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

News Alert

FDA, FTC warn 10 companies for making ‘fraudulent claims’ about unapproved diabetes supplements

Each company is believed to be in violation of the Federal Food, Drug and Cosmetic Act. They have 15 working days to respond. 

READ MORE >
pills-384846_960_720.jpg
Share on Twitter Share on Facebook Share on Linkedin

FDA, FTC warn 10 companies for making ‘fraudulent claims’ about unapproved diabetes supplements

Share on Twitter Share on Facebook Share on Linkedin
pills-384846_960_720.jpg
Each company is believed to be in violation of the Federal Food, Drug and Cosmetic Act. They have 15 working days to respond. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Cardiologists scramble to prepare for new policy | Boston Scientific invests $1.5B in TAVR developer | FDA clears cath lab tech
The latest on PFA risks | EP catheters recalled | Doctors exempt from work visa freeze | Good news for Heartflow
Top 10 most popular cardiology video interviews this past month
Week in Review: New IVL data | TAVR trend prompts 'call to action' | Compensation climbs | Ablations in ASCs | More recalls
News Alert: Thousands of reprocessed EP catheters recalled
New heart failure device impresses | Cardiac amyloidosis in the spotlight | Experts agree: HFmrEF should not be ignored
Cardiology salaries outpace other specialties | A new TAVR technique | Cardiac amyloidosis in the spotlight | BP drug recalled

Pagination

    • First page « First
    • Previous page ‹‹
    • Page …4
    • Page 5
    • Page 6
    • Page 7
    • Current page 8
    • Page 9
    • Page 10
    • Page 11
    • Page 12 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme